Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Recombinant human erythropoietin (rhEPO) is receiving increasing attention as a potential therapy for prevention of injury and restoration of function in nonhematopoietic tissues. However, the minimum effective dose required to mimic and augment these normal paracrine functions of erythropoietin (EPO) in some organs (e.g., the brain) is higher than for treatment of anemia. Notably, a dose-dependent risk of adverse effects has been associated with rhEPO administration, especially in high-risk groups, including polycythemia–hyperviscosity syndrome, hypertension, and vascular thrombosis. Of note, several clinical trials employing relatively high dosages of rhEPO in oncology patients were recently halted after an increase in mortality and morbidity, primarily because of thrombotic events. We recently identified a heteromeric EPO receptor complex that mediates tissue protection and is distinct from the homodimeric receptor responsible for the support of erythropoiesis. Moreover, we developed receptor-selective ligands that provide tools to assess which receptor isoform mediates which biological consequence of rhEPO therapy. Here, we demonstrate that rhEPO administration in the rat increases systemic blood pressure, reduces regional renal blood flow, and increases platelet counts and procoagulant activities. In contrast, carbamylated rhEPO, a heteromeric receptor-specific ligand that is fully tissue protective, increases renal blood flow, promotes sodium excretion, reduces injury-induced elevation in procoagulant activity, and does not effect platelet production. These preclinical findings suggest that nonerythropoietic tissue-protective ligands, which appear to elicit fewer adverse effects, may be especially useful in clinical settings for tissue protection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2153]
Citations
Cites
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 2,005
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationDerivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citationErythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.-W., Smart, J., Su-Rick, C.-J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406491101 · Cited by 656
Self-citationRisk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T. R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021067 · Cited by 527
Self-citationEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Self-citationBreast cancer trial with erythropoietin terminated unexpectedly
Leyland-Jones, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01163-x · Cited by 474
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Lampugnani, M. G., Zanetti, A., Corada, M., Takahashi, T., Balconi, G., Breviario, F., Orsenigo, F., Cattelino, A., Kemler, R., Daniel, T. O., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209019 · Cited by 410
Self-citationMolecular mechanisms of leukocyte recruitment in the inflammatory process
Ley, K. (1996) · Cardiovascular Research · doi:10.1016/0008-6363(96)00066-1 · Cited by 395
Erythropoietin and VEGF Exhibit Equal Angiogenic Potential
Jaquet, K., Krause, K., Tawakol-Khodai, M., Geidel, S., & Kuck, K.-H. (2002) · Microvascular Research · doi:10.1006/mvre.2002.2426 · Cited by 317
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans
Stohlawetz, P. J., Dzirlo, L., Hergovich, N., Lackner, E., Mensik, C., Eichler, H. G., Kabrna, E., Geissler, K., & Jilma, B. (2000) · Blood · doi:10.1182/blood.v95.9.2983.009k27_2983_2989 · Cited by 293
Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus
Juul, S. E., Yachnis, A. T., & Christensen, R. D. (1998) · Early Human Development · doi:10.1016/s0378-3782(98)00030-9 · Cited by 289
Epoetin requirements predict mortality in hemodialysis patients
Zhang, Y., Thamer, M., Stefanik, K., Kaufman, J., & Cotter, D. J. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01086-8 · Cited by 271
Yasuda, Y., Masuda, S., Chikuma, M., Inoue, K., Nagao, M., & Sasaki, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25381 · Cited by 262
Human, rat, and mouse kidney cells express functional erythropoietin receptors
Westenfelder, C., Biddle, D. L., & Baranowski, R. L. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055003808.x · Cited by 246
Self-citationErgogenic Aids: A Review of Basic Science, Performance, Side Effects, and Status in Sports
Tokish, J. M., Kocher, M. S., & Hawkins, R. J. (2004) · The American Journal of Sports Medicine · doi:10.1177/0363546504268041 · Cited by 184
Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels
Heidenreich, S., Rahn, K.-H., & Zidek, W. (1991) · Kidney International · doi:10.1038/ki.1991.31 · Cited by 183
Wun, T., Law, L. Y., Harvey, D. J., Sieracki, B., Scudder, S., & Ryu, J. K. (2003) · Cancer · doi:10.1002/cncr.11700 · Cited by 139
Ando, M., Iwata, A., Ozeki, Y., Tsuchiya, K., Akiba, T., & Nihei, H. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00627.x · Cited by 128
Gorio, A., Madaschi, L., Di Stefano, B., Carelli, S., Di Giulio, A. M., De Biasi, S., Coleman, T., Cerami, A., & Brines, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508479102 · Cited by 127
Self-citationHedgehog Signaling in Murine Vasculogenesis and Angiogenesis
Byrd, N. A., & Grabel, L. B. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2004.09.003 · Cited by 126
Effect of recombinant human erythropoietin on endothelial cell apoptosis
Carlini, R. G., Alonzo, E., Domínguez, J. N., Blanca, I., Weisinger, J. R., Rothstein, M., & Bellorín-Font, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00266.x · Cited by 105
Yasuda, Y., Musha, T., Tanaka, H., Fujita, Y., Fujita, H., Utsumi, H., Matsuo, T., Masuda, S., Nagao, M., Sasaki, R., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1666 · Cited by 101
Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Abraham, P. A., & Macres, M. G. (1991) · Journal of the American Society of Nephrology · doi:10.1681/asn.v24927 · Cited by 100
Characterization of neurosphere cell phenotypes by flow cytometry
Hulspas, R., & Quesenberry, P. J. (2000) · Cytometry · doi:10.1002/1097-0320(20000701)40:3<238::aid-cyto9>3.0.co;2-3 · Cited by 95
Contribution of Bone Marrow-Derived Cells to Blood Vessels in Ischemic Tissues and Tumors
Aghi, M. K., & Chiocca, E. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.693 · Cited by 94
The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
Rosenzweig, M. Q., Bender, C. M., Lucke, J. P., Yasko, J. M., & Brufsky, A. (2004) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2003.06.010 · Cited by 93
Hypertension Following Erythropoietin Therapy in Anemic Hemodialysis Patients
Buckner, F. S., Eschbach, J. W., Haley, N. R., Davidson, R. C., & Adamson, J. W. (1990) · American Journal of Hypertension · doi:10.1093/ajh/3.12.947 · Cited by 92
Fusté, B., Serradell, M., Escolar, G., Cases, A., Mazzara, R., Castillo, R., Ordinas, A., & Díaz‐Ricart, M. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613275 · Cited by 90
Ammarguellat, F., Gogusev, J., & Drüeke, T. B. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.4.687 · Cited by 90
Nomura, S., Nakamura, T., Cone, J. L., Tandon, N. N., & Kambayashi, J. (2000) · Cytometry · doi:10.1002/1097-0320(20000701)40:3<173::aid-cyto1>3.0.co;2-l · Cited by 78
In vivo and in vitro pressor effects of erythropoietin in rats
Vaziri, N. D., Zhou, X. J., Smith, J., Oveisi, F., Baldwin, K., & Purdy, R. E. (1995) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1995.269.6.f838 · Cited by 76
Moon, C., Krawczyk, M., Paik, D., Lakatta, E. G., & Talan, M. I. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-3189-6 · Cited by 75
Erythropoietin Administration Increases Production and Reactivity of Platelets in Dogs
Wolf, R. F., Peng, J., Friese, P., Gilmore, L. S., Burstein, S. A., & Dale, G. L. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1665442 · Cited by 74
Rameshwar, P., Chang, V. T.-S., Thacker, U. F., & Gascón, P. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199810)59:2<121::aid-ajh4>3.0.co;2-# · Cited by 61
Unexpected Renal Actions of Erythropoietin
Westenfelder, C. S. (2002) · Nephron Experimental Nephrology · doi:10.1159/000065304 · Cited by 58
Self-citationCotter, D. J., Stefanik, K., Zhang, Y., Thamer, M., Scharfstein, D. O., & Kaufman, J. S. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.05.002 · Cited by 55
Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells
Neusser, M., Tepel, M., & Zidek, W. (1993) · Cardiovascular Research · doi:10.1093/cvr/27.7.1233 · Cited by 54
Erythropoietin Potentiates Thrombus Development in a Canine Arterio-Venous Shunt Model
Wolf, R. F., Gilmore, L. S., Friese, P., Downs, T., Burstein, S. A., & Dale, G. L. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656096 · Cited by 50
Erythropoietin Administration In Vivo Increases Vascular Nitric Oxide Synthase Expression
Kanagy, N. L., Perrine, M. F., Cheung, D. K., & Walker, B. R. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200310000-00011 · Cited by 47
Tàssies, D., Reverter, J. C., Cases, A., Calls, J., Escolar, G., & Ordinas, A. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199810)59:2<105::aid-ajh1>3.0.co;2-1 · Cited by 39
Saray, A., Ozakpinar, R., Koç, C., Serel, S., Şen, Z. B., & Can, Z. (2003) · The Laryngoscope · doi:10.1097/00005537-200301000-00016 · Cited by 31
Clyne, N., Berglund, B., & Egberg, N. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)91520-u · Cited by 29
Erythropoietin and hypertension.
Nowicki, M. P. (1995) · PubMed · Cited by 27
Grossman, H. A., Goon, B. L., Bowers, P., & Leitz, G. J. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00003 · Cited by 26
Lin, A., Ryu, J. K., Harvey, D. J., Sieracki, B., Scudder, S., & Wun, T. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.11.031 · Cited by 19
Aguilera, A., Selgas, R., Ruiz-Caravaca, M. L., Bajo, M. A., Cuesta, M. V., Plaza, M. A., & Hernánz, Á. (1999) · Peritoneal Dialysis International · doi:10.1177/089686089901902s25 · Cited by 19
Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells
Hale, S. A., Wong, C., & Lounsbury, K. M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.056 · Cited by 16
Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys.
Brier, M. E., Bunke, C. M., Lathon, P. V., & Aronoff, G. R. (1993) · Journal of the American Society of Nephrology · doi:10.1681/asn.v391583 · Cited by 16
Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients
Kahraman, S., Yılmaz, R., Kırkpantur, A., Gençtoy, G., Arıcı, M., Altun, B., Erdem, Y., Yasavul, Ü., & Turgan, Ç. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00405.x · Cited by 15
Creutzig, A., Caspary, L. A., Nonnast-Daniel, B., Bahlmann, J., KÜHN, K., Brunkhorst, R., REIMERS, E., Koch, K. M., & ALEXANDER, K. (1990) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1990.tb02272.x · Cited by 12
Recombinant Human Erythropoietin Stimulates Tubular Reabsorption of Sodium in Anesthetized Rabbits.
Nushiro, N., Sakamaki, T., Hoshino, J., Nakamura, T., Sakamoto, H., Imai, Y., SEINO, M., Omata, K., Sekino, H., & Abe, K. (1995) · Hypertension Research · doi:10.1291/hypres.18.203 · Cited by 10
Study of the actions of human recombinant erythropoietin on rat renal haemodynamics
Huang, C., Davis, G., & Johns, E. J. (1992) · Clinical Science · doi:10.1042/cs0830453 · Cited by 10
Santini, D., Vincenzi, B., Cesa, A. L., Virzì, V., Navajas, F., Malafarina, V., Dicuonzo, G., Cassandro, R., Esposito, V., Montesarchio, V., et al. (2005) · PubMed · Cited by 9
Effect of erythropoietin on renal excretion of a sodium load
Bunke, M. C., Gleason, J. R., Brier, M. E., & Sloan, R. S. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.70 · Cited by 8
Ishikawa, A., Suzuki, K. T., & Fujita, K. (1999) · Urological Research · doi:10.1007/s002400050156 · Cited by 7
Research works printed but not linked: 6
- D. Santini, B. Vincenzi, A. La Cesa, V. Virzi, F. Navajas, V. Malafarina, G. Dicuonzo, R. Cassandro, V. Esposito, V. Montesarchio, et al. Anticancer Res 25, 669–674 (2005).
- N. D. Vaziri, X. J. Zhou, J. Smith, F. Oveisi, K. Baldwin, R. E. Purdy Am. J. Physiol 269, F838–F845 (1995).
- M. Nowicki J. Hum. Hypertens 9, 81–88 (1995).
- A. Lin, J. Ryu, D. Harvey, B. Sieracki, S. Scudder, T. Wun Gynecol. Oncol, 2006).
- 10.1016/s0008-6363(96)00066-1 · doi:10.1016/s0008-6363(96)00066-1 · Paper page
- 10.1093/oxfordjournals.ndt.a027361 · doi:10.1093/oxfordjournals.ndt.a027361 · Paper page
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Brines, M., & Cerami, A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02024.x · Cited by 333
Self-citationSimon, F., Scheuerle, A., Gröger, M., Vcelar, B. A., McCook, O., Möller, P., Georgieff, M., Calzia, E., Radermacher, P., & Schelzig, H. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2303-4 · Cited by 315
Erythropoietin and renoprotection
Bahlmann, F. H., & Fliser, D. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32831a9dde · Cited by 298
Metadata
- Authors
- Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M.
- Affiliations
- Verona Pharma (United Kingdom) (GB)
- University of Utah (US)
- Departments of Medicine and Physiology, University of Utah and Veterans Affairs Medical Centers, Salt Lake City, UT 84148;
- University of Groningen (NL)
- Mayo Clinic (US)
- University of Groningen, 9700 AB, Groningen, The Netherlands;
- Mario Negri Institute for Pharmacological Research (IT)
- University of California San Diego (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-04-11
- Volume
- 103
- Issue
- 15
- Pages
- 5965-5970
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106292297
- Cited by
- 127
- References
- 62
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 9 · 2012: 7
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (R01CA031615)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- recombinant human erythropoietin, carbamylated erythropoietin, erythropoietin receptor, heteromeric receptors, procoagulant activity, platelet count, blood pressure, renal blood flow, sodium excretion, tissue protection, thrombosis, dose-dependent adverse effects, paracrine effects
- MeSH terms
- Animals, Blood Coagulation, Blood Pressure, Bone Marrow Cells, Cell Line, Coagulants, Endothelium, Vascular, Erythropoietin, Hematopoiesis, Hemodynamics, Humans, Renal Circulation, Stem Cells, Umbilical Veins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.